ISSN 0970-7700
 
2020, Vol: 26, Issue: 2
26 / 2Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

1. JREIM Covering Letter and Authors Declaration Form (Section 1-5) Ver. Jan 2021
2. TITLE page - Abstract - References etc-Sections -1 to 6 (NEW 2020-21)
3.JREIM Proforma for Authors CV and Declaration cum Consent Form-Ver-R -151022
4. JREIM Template for Submitting Manuscript in JREIM

Original Research
Online Published: 15 Jun 2015
 


CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY

N.B.GHIWARE, T.M.NESARI, N.Y.GOND.


Abstract
An uncontrolled, open label clinical study was done on twenty-one smear
positive patients of Plasmodium vivax malaria. High solid content deflocculated suspension
of Piper nigrum and Nyctanthes arbortristis was given to patients after their enrollment
in study. Vital signs and symptoms of malaria as body temperature, chilly felling/rigors,
headache, body ache, nausea/vomiting and anemia were recorded before treatment, after
first and second week of treatment. Improvement in condition was recorded as shifting
of gradation in signs of malaria. Decrease in increased body temperature was recorded
at the end of first week of treatment (P<0.001). Global assessment suggests improvement
within first week of treatment from chilly felling/rigors, headache and body ache. Recovery
from nausea/vomiting and anemic signs was observed only after second week of treatment.
Negative smear test for Plasmodium vivax was observed at the end of treatment schedule
in all patients.

Key words: Polyherbal formulation, Plasmodium vivax, Antimalarial medicine, Piper nigrum, Nyctanthes arbortristis, Medicinal plants.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by N.B.GHIWARE
Articles by T.M.NESARI
Articles by N.Y.GOND
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND. CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY . J Res Educ Indian Med . 2007; 13(1): 33-38.

Web Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND. CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY . https://www.jreim-ayushjournal.com/?mno=191590 [Access: September 13, 2024].

AMA (American Medical Association) Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND. CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY . J Res Educ Indian Med . 2007; 13(1): 33-38.


Vancouver/ICMJE Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND. CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY . J Res Educ Indian Med . (2007), [cited September 13, 2024]; 13(1): 33-38.


Harvard Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND (2007) CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY . J Res Educ Indian Med , 13 (1), 33-38.


Turabian Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND. 2007. CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY . Journal of Research and Education in Indian Medicine, 13 (1), 33-38.


Chicago Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND. "CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY ." Journal of Research and Education in Indian Medicine 13 (2007), 33-38.


MLA (The Modern Language Association) Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND. "CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY ." Journal of Research and Education in Indian Medicine 13.1 (2007), 33-38. Print.


APA (American Psychological Association) Style

N.B.GHIWARE, T.M.NESARI, N.Y.GOND (2007) CLINICAL VALIDATION OF Piper nigrum AND Nyctanthes arbortristis FORMULATION FOR ANTIMALARIAL ACTIVITY . Journal of Research and Education in Indian Medicine, 13 (1), 33-38.


Author LoginReviewer LoginAbout PublisherEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPrivacy PolicyAdvertising PolicyLicense InformationCopyright Information

About Journal of Research and Education in Indian Medicine

The Journal of Research & Education in Indian Medicine (JREIM) is a quarterly peer-reviewed international journal. JREIM has been established and laun ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Websites
http://www.jreim-ayushjournal.com  and  
​http://www.ejmanager.com/my/jreim 
 

JREIM Head Office
B 29/19 Lanka, PO: BHU, Varanasi-221005 UP (India)   
e-mail:  jreim@ejmanager.com,
Tel: (+91) 9305180763

 

If you need to contact an editor, please use the contact details below:
e-mail: editor@jreim-ayushjournal.com, drlaxmi_ayush_journal@yahoo.com
Tel.: (+91) 9305180763 during office hours (10 AM to 5 PM, Monday to Friday)

Rana Gopal Singh, MD, DM
Editor-in- Chief, Integrative Medicine
 rgsingh@bhu.ac.in, profrgsingh@yahoo.com,  

Suresh Kumar, MD (Ayurveda), PhD
Editor-in- Chief, Ayurveda and Yoga
editor-in-chief@jreim-ayushjournal.com,  prof.suresh.india@gmail.com

Change of Address:
To change address or update your personal information, kindly visit your account (author/reviewer/editor) at http://www.ejmanager.com/my/jreim and update your profile.

If you have further queries, we would be happy to answer those. Please send
your queries to  manager@jreim-ayushjournal.com  or call us on +91 9305180763. 

------------------------

Medical advice:
JREIM (http://www.jreim-ayushjournal.com) does not give medical advice and will not be able to respond to inquiries about specific diseases, medical or surgical conditions, diagnosis, treatments or contact of another person.

Authors Contact:
To contact a author, use the information provided with the manuscript; JREIM will not be able to provide additional details.